[Source: GenomeWeb News] – Thermo Fisher Scientific and Intrinsic Bioprobes today announced an agreement to co-develop and market a mass spectrometry-based solution for researchers to do quantitative, high-throughput, and high resolution protein biomarker assays.
Under the agreement, IBI’s proprietary immunoenrichment technology will be integrated with Thermo Fisher’s sample handling and mass specs, providing “researchers with a more complete, higher-resolution view of the proteome,” Thermo Fisher said in a statement.
Via a reseller agreement, the solution will initially be used to detect human parathyroid hormone, or PTH, and its variants, which have the potential to be used as biomarkers for bone disease and endocrinological disease.
For more information: Thermo Fisher, Intrinsic Bioprobes Partner to Develop Mass Spec Assays